Molecular Design Using the Minireceptor Concept

Explicit molecular binding pockets were constructed and optimized around sets of superimposed ligands using the minireceptor concept. The resulting binding sites incorporate the properties of the different ligands and were shown to be suitable for the design of molecules presenting novel interaction patterns. Two applications of minireceptor construction and/or optimization, followed by molecular design are described. In the pursuit of new ligands mimicking the action of paclitaxel, a minireceptor was constructed using the primary amino acid sequence of the target protein as a guide. The active site extracted from a homology-based model of the serotonin 5-HT1A receptor was optimized around a set of three ligands using the same approach.

[1]  D. Kingston,et al.  Taxol: the chemistry and structure-activity relationships of a novel anticancer agent. , 1994, Trends in biotechnology.

[2]  James P. Snyder,et al.  Pseudoreceptor Modeling: The Construction of Three-Dimensional Receptor Surrogates , 1995 .

[3]  I. Ringel,et al.  3'-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin. , 1994, The Journal of biological chemistry.

[4]  P. Schiff,et al.  Taxol stabilizes microtubules in mouse fibroblast cells. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[5]  B. Gillet,et al.  Conformation of Taxotere® and analogues determined by NMR spectroscopy and molecular modeling studies , 1993 .

[6]  R. Himes,et al.  Synthesis of a photoaffinity taxol analogue and its use in labeling tubulin. , 1994, Journal of medicinal chemistry.

[7]  H. Williams,et al.  NMR and molecular modeling study of the conformations of taxol and of its side chain methylester in aqueous and non-aqueous solution. , 1993 .

[8]  D. Kingston,et al.  The chemistry of taxol. , 1991, Pharmacology & therapeutics.

[9]  D Rognan,et al.  A pseudo-particle approach for studying protein-ligand models truncated to their active sites. , 1998, Biopolymers.

[10]  S. Hjorth,et al.  10-substituted 11-oxygenated (R)-aporphines: synthesis, pharmacology, and modeling of 5-HT1A receptor interactions. , 1996, Journal of medicinal chemistry.

[11]  D. Guénard,et al.  Taxol and Taxotere: Discovery, Chemistry, and Structure‐Activity Relationships , 1993 .

[12]  U. Hacksell,et al.  Molecular basis for the binding of 2-aminotetralins to human dopamine D2A and D3 receptors. , 1994, Molecular pharmacology.

[13]  M. Houslay G‐protein linked receptors: a family probed by molecular cloning and mutagenesis procedures , 1992, Clinical endocrinology.

[14]  D. E. Clark,et al.  PRO_LIGAND: an approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores. , 1994, Journal of medicinal chemistry.

[15]  D. Gibson,et al.  Photocyclization of aryl-substituted acetylenesi application of di-.pi.-methane-like rearrangements to arylcyclopropene syntheses , 1971 .

[16]  H. Williams,et al.  NMR and molecular modeling study of active and inactive taxol analogues in aqueous and nonaqueous solution , 1994 .

[17]  A. Vedani,et al.  Pseudo-receptor modeling: a new concept for the three-dimensional construction of receptor binding sites. , 1993, Journal of receptor research.

[18]  M. Hamon Neuropharmacology of anxiety: perspectives and prospects. , 1994, Trends in pharmacological sciences.

[19]  Y. Martin,et al.  3D database searching in drug design. , 1992, Journal of medicinal chemistry.

[20]  J Hoflack,et al.  Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. , 1991, Molecular pharmacology.

[21]  Richard Henderson,et al.  A model for the structure of bacteriorhodopsin based on high resolution electron cryomicroscopy , 1990 .

[22]  B. Max This and that: sequential theories for stomach cancer and the multiple applications of isotopic ratios. , 1992, Trends in pharmacological sciences.

[23]  J J Baldwin,et al.  Application of the three-dimensional structures of protein target molecules in structure-based drug design. , 1994, Journal of medicinal chemistry.

[24]  U. Hacksell,et al.  Binding-site modeling of the muscarinic m1 receptor: a combination of homology-based and indirect approaches. , 1993, Journal of medicinal chemistry.

[25]  R. Henderson,et al.  Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. , 1990, Journal of molecular biology.

[26]  B. Matthews,et al.  Molecular basis of thermostability in the lysozyme from bacteriophage T4 , 1979, Nature.

[27]  S. Hjorth,et al.  (R)-11-hydroxy- and (R)-11-hydroxy-10-methylaporphine: synthesis, pharmacology, and modeling of D2A and 5-HT1A receptor interactions. , 1995, Journal of medicinal chemistry.

[28]  James B. Dunbar,et al.  Chapter 29. 3D Database Searching and Docking Strategles , 1993 .

[29]  S. Fesik,et al.  NMR studies of molecular complexes as a tool in drug design. , 1991, Journal of medicinal chemistry.

[30]  J. Jansen,et al.  The high affinity melationin binding site probed with conformationally restricted ligand--I. Pharmacophore and minireceptor models. , 1996, Bioorganic & medicinal chemistry.

[31]  Garland R. Marshall,et al.  The Conformational Parameter in Drug Design: The Active Analog Approach , 1979 .

[32]  S. Horwitz,et al.  Mechanism of action of taxol. , 1992, Trends in pharmacological sciences.

[33]  Andrew R. Leach,et al.  Current methods for site-directed structure generation , 1994, J. Comput. Aided Mol. Des..

[34]  C. Fraser,et al.  In vitro mutagenesis and the search for structure-function relationships among G protein-coupled receptors. , 1992, The Biochemical journal.

[35]  C. Humblet,et al.  Chapter 30. Three-dimensional Models of G-Protein Coupled Receptors , 1992 .

[36]  D. Rognan,et al.  MD simulations in Pseudo-Particle Fluids: Applications to active-site Protein Complexes , 1995 .

[37]  A. McPhail,et al.  Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. , 1971, Journal of the American Chemical Society.

[38]  J Hoflack,et al.  Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors. , 1992, Journal of medicinal chemistry.

[39]  Angelo Vedani,et al.  A new force field for modeling metalloproteins , 1990 .

[40]  J. Taylor‐Papadimitriou,et al.  Exploiting altered glycosylation patterns in cancer: progress and challenges in diagnosis and therapy. , 1994, Trends in biotechnology.

[41]  P. Schiff,et al.  Promotion of microtubule assembly in vitro by taxol , 1979, Nature.

[42]  M. Suffness,et al.  Chapter 32. Taxol: From Discovery to Therapeutic Use , 1993 .